Will Kyle Bass's Win Lead To More Hedge Fund Patent Challenges?

HFA Padded
Mark Melin
Published on
Updated on
Kyle Bass

As the sting of hedge fund manager Martin Shkreli’s Turing Pharmaceuticals raising the price of an important drug from $13.50 per tablet to $750, comes a victory for hedge fund manager Kyle Bass, who is challenging pharmaceutical patents and says his actions will lower drug prices. U.S. Patent and Trademarket Office rules with Kyle Bass In a victory for Bass, a tribunal at the U.S. Patent and Trademark Office was reported on Friday to have denied a request by Celgene Corp to sanction Bass and his Coalition for Affordable Drugs by throwing out their challenges to its patents. In an…

This content is exclusively for paying members of Hedge Fund Alpha

Log In

Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha

Don’t have an account?

Subscribe now and get 7 days free!

HFA Padded

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.